TABLE 5.
In vitro activities of ceftazidime-avibactam and comparator agents tested against 1,926 meropenem-nonsusceptible P. aeruginosa isolates collected in 2012 to 2014 from patients in four geographic regions
| Region (no. of isolates) | Antimicrobial agenta | MIC90 (μg/ml) | % Susceptibleb |
|---|---|---|---|
| All (1,926) | Ceftazidime-avibactam | 64 | 72.4 |
| Ceftazidime | 128 | 42.4 | |
| Cefepime | >16 | 41.0 | |
| Piperacillin-tazobactam | >128 | 28.4 | |
| Doripenem | >4 | 9.3 | |
| Meropenem | >8 | 0 | |
| Imipenem | >8 | 4.8 | |
| Colistin | 1 | 99.2 | |
| Amikacin | >32 | 67.4 | |
| Levofloxacin | >4 | 34.0 | |
| Europe (1,056) | Ceftazidime-avibactam | 32 | 74.2 |
| Ceftazidime | 128 | 41.3 | |
| Cefepime | >16 | 41.0 | |
| Piperacillin-tazobactam | >128 | 27.0 | |
| Doripenem | >4 | 9.8 | |
| Meropenem | >8 | 0 | |
| Imipenem | >8 | 4.7 | |
| Colistin | 1 | 99.3 | |
| Amikacin | >32 | 68.1 | |
| Levofloxacin | >4 | 33.0 | |
| Asia/South Pacific (314) | Ceftazidime-avibactam | 128 | 71.7 |
| Ceftazidime | >128 | 45.5 | |
| Cefepime | >16 | 43.0 | |
| Piperacillin-tazobactam | >128 | 30.6 | |
| Doripenem | >4 | 9.2 | |
| Meropenem | >8 | 0 | |
| Imipenem | >8 | 5.7 | |
| Colistin | 1 | 99.0 | |
| Amikacin | >32 | 78.7 | |
| Levofloxacin | >4 | 39.5 | |
| Latin America (382) | Ceftazidime-avibactam | 32 | 70.2 |
| Ceftazidime | >128 | 40.3 | |
| Cefepime | >16 | 38.5 | |
| Piperacillin-tazobactam | >128 | 29.1 | |
| Doripenem | >4 | 7.6 | |
| Meropenem | >8 | 0 | |
| Imipenem | >8 | 5.0 | |
| Colistin | 1 | 99.0 | |
| Amikacin | >32 | 56.8 | |
| Levofloxacin | >4 | 30.1 | |
| Middle East/Africa (174) | Ceftazidime-avibactam | 64 | 67.8 |
| Ceftazidime | 128 | 48.3 | |
| Cefepime | >16 | 42.5 | |
| Piperacillin-tazobactam | >128 | 31.6 | |
| Doripenem | >4 | 9.8 | |
| Meropenem | >8 | 0 | |
| Imipenem | >8 | 3.5 | |
| Colistin | 1 | 98.9 | |
| Amikacin | >32 | 66.1 | |
| Levofloxacin | >4 | 39.1 |
a
Colistin was tested in the presence of a final concentration of 0.002% polysorbate 80.
b
Values are based on CLSI breakpoints, except for ceftazidime-avibactam, for which FDA breakpoints were used.